Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15079885 | 0.85 | TSHR (0.57) | KMT2AMEN1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL15079780 | 0.82 | USP2 (0.44) | ADRB1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1496709 | 0.80 | ADRB2 (0.55) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL15079364 | 0.78 | MEN1 (0.47) | KMT2AMEN1L3MBTL1MAPTHTT | |
| SCHEMBL10922740 | 0.77 | ADRB2 (0.71) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL15079881 | 0.77 | LTA4H (0.49) | ADRB2ADRB1L3MBTL1MAPTHTT | |
| SCHEMBL15079914 | 0.77 | TSHR (0.46) | KMT2AMEN1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL30416351 | 0.76 | ADRB2 (0.65) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL1496566 | 0.76 | ADRB2 (0.65) | ADRB2ADRB1KMT2AMEN1L3MBTL1 | |
| SCHEMBL15079749 | 0.75 | MAPT (0.44) | KMT2AMEN1MAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| WO-2013093320-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | ARG1, TYR, NOS1 | ADRB2 1145/4885ADRB1 561/4885KMT2A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.